Short Interest in Prenetics Global Limited (NASDAQ:PRE) Declines By 18.1%

Prenetics Global Limited (NASDAQ:PRE) was the recipient of a large drop in short interest during the month of March. As of March 31st, there was short interest totalling 32,200 shares, a drop of 18.1% from the March 15th total of 39,300 shares. Based on an average daily trading volume, of 11,900 shares, the short-interest ratio is currently 2.7 days. Currently, 0.4% of the company’s stock are short sold.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald restated an “overweight” rating and issued a $9.00 price objective on shares of Prenetics Global in a research note on Thursday, January 16th.

Prenetics Global Price Performance

NASDAQ:PRE opened at $3.97 on Friday. The company has a market capitalization of $48.45 million, a PE ratio of -0.99 and a beta of -0.20. Prenetics Global has a 52-week low of $2.95 and a 52-week high of $7.84. The stock’s 50 day moving average price is $4.42 and its 200 day moving average price is $4.86.

Hedge Funds Weigh In On Prenetics Global

An institutional investor recently bought a new position in Prenetics Global stock. Quinn Opportunity Partners LLC purchased a new position in shares of Prenetics Global Limited (NASDAQ:PRE) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 12,339 shares of the company’s stock, valued at approximately $72,000. Quinn Opportunity Partners LLC owned 0.10% of Prenetics Global at the end of the most recent reporting period. 25.01% of the stock is currently owned by hedge funds and other institutional investors.

Prenetics Global Company Profile

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.